.0B, trading at HK$7.80 on the HKSE. This SniperIQ fundamentals page covers TYK Medicines's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
.0B
Net Margin0.0%

Full research coverage

Frequently Asked Questions

What is TYK Medicines's market cap?

TYK Medicines (2410) has a market capitalization of approximately HK

.0B, trading at HK$7.80 on the HKSE. Market cap moves with the live share price.

What is TYK Medicines's P/E ratio?

TYK Medicines's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 8.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is TYK Medicines?

TYK Medicines runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does TYK Medicines pay a dividend?

TYK Medicines does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is TYK Medicines financially healthy?

TYK Medicines carries a debt-to-equity ratio of 0.53x and a current ratio of 1.43x, with a market beta of 2.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is TYK Medicines a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TYK Medicines (2410) the key facts are: market cap HK

.0B, 52-week range 5.35-25.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track TYK Medicines's full fundamentals live

Get TYK Medicines's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.